Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®

Contributed by: PR Newswire

Tags

CALLIDITAS

More Like This

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Calliditas provides patent update

Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®

Calliditas Year-end report, January - December 2023

Calliditas Interim Report January - September 2023

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

Calliditas Q1 report, January - March 2024

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress